دورية أكاديمية
أعرض في EDS

Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells.

التفاصيل البيبلوغرافية
العنوان: Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells.
المؤلفون: Lindner D; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.; Tumor Immunology, University Hospital Carl Gustav Carus, University Cancer Center (UCC), Technical University Dresden, 01307 Dresden, Germany., Arndt C; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany., Loureiro LR; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany., Feldmann A; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany., Kegler A; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany., Koristka S; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany., Berndt N; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany., Mitwasi N; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany., Bergmann R; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.; Institute of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary., Frenz M; Faculty Informatik and Wirtschaftsinformatik, Provadis School of International Management and Technology AG, 65926 Frankfurt, Germany., Bachmann MP; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.; National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Jul 18; Vol. 23 (14). Date of Electronic Publication: 2022 Jul 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Antibodies, Bispecific* , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/radiotherapy, Humans ; Immunologic Factors ; Immunotherapy/methods ; Male ; T-Lymphocytes
مستخلص: Radiation of tumor cells can lead to the selection and outgrowth of tumor escape variants. As radioresistant tumor cells are still sensitive to retargeting of T cells, it appears promising to combine radio- with immunotherapy keeping in mind that the radiation of tumors favors the local conditions for immunotherapy. However, radiation of solid tumors will not only hit the tumor cells but also the infiltrated immune cells. Therefore, we wanted to learn how radiation influences the functionality of T cells with respect to retargeting to tumor cells via a conventional bispecific T cell engager (BiTE) and our previously described modular BiTE format UNImAb. T cells were irradiated between 2 and 50 Gy. Low dose radiation of T cells up to about 20 Gy caused an increased release of the cytokines IL-2, TNF and interferon-γ and an improved capability to kill target cells. Although radiation with 50 Gy strongly reduced the function of the T cells, it did not completely abrogate the functionality of the T cells.
References: N Engl J Med. 2018 Feb 15;378(7):645-657. (PMID: 29412780)
JAMA Oncol. 2018 Nov 1;4(11):1553-1568. (PMID: 29860482)
Cancer Immunol Immunother. 2019 Oct;68(10):1713-1719. (PMID: 31542798)
Oncoimmunology. 2020 Jul 3;9(1):1785608. (PMID: 32923149)
JAMA. 1998 Sep 16;280(11):969-74. (PMID: 9749478)
Nat Biotechnol. 2013 Jan;31(1):71-5. (PMID: 23242161)
Lancet Oncol. 2014 Jun;15(7):700-12. (PMID: 24831977)
Cancers (Basel). 2019 Jun 21;11(6):. (PMID: 31234336)
Cells. 2022 Jun 06;11(11):. (PMID: 35681548)
Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705)
Cancers (Basel). 2012 Feb 22;4(1):193-217. (PMID: 24213236)
J Biomed Biotechnol. 2010;2010:956304. (PMID: 20467460)
Lancet Oncol. 2009 Jul;10(7):718-26. (PMID: 19573801)
Anal Biochem. 2012 Apr 15;423(2):261-8. (PMID: 22274538)
J Autoimmun. 2013 May;42:105-16. (PMID: 23352111)
Hum Gene Ther. 2021 Oct;32(19-20):1011-1028. (PMID: 34405686)
Front Immunol. 2022 May 19;13:883639. (PMID: 35663987)
Drugs Today (Barc). 2017 Nov;53(11):597-608. (PMID: 29451276)
Blood Cancer J. 2017 Dec 20;7(12):659. (PMID: 29259173)
Cancers (Basel). 2022 Mar 25;14(7):. (PMID: 35406454)
Cancer Discov. 2022 Jan;12(1):108-133. (PMID: 34479871)
Cancers (Basel). 2021 Feb 01;13(3):. (PMID: 33535559)
Cancer Lett. 2006 May 18;236(2):229-38. (PMID: 16046056)
Nat Rev Drug Discov. 2019 Nov;18(12):899-900. (PMID: 31780841)
Leukemia. 2011 Jun;25(6):1053-6. (PMID: 21415850)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
Nat Commun. 2020 Jul 30;11(1):3801. (PMID: 32732879)
N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127)
Oncotarget. 2018 May 22;9(39):25597-25616. (PMID: 29876011)
Nat Rev Cancer. 2016 Apr;16(4):234-49. (PMID: 27009394)
Int J Mol Sci. 2016 Jan 14;17(1):. (PMID: 26784176)
Ann Oncol. 2020 Sep;31(9):1119-1134. (PMID: 32593798)
J Immunol. 2012 Feb 1;188(3):1551-8. (PMID: 22184723)
Cancers (Basel). 2021 Sep 24;13(19):. (PMID: 34638268)
Int J Mol Sci. 2021 Mar 25;22(7):. (PMID: 33806091)
Prostate. 2014 Sep;74(13):1347-58. (PMID: 25053504)
Nat Rev Clin Oncol. 2020 Jul;17(7):418-434. (PMID: 32242094)
Oncoimmunology. 2020 Apr 5;9(1):1743036. (PMID: 32426176)
Immunol Lett. 2019 Jul;211:13-22. (PMID: 31091431)
Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310)
Cancer Cell. 2013 Nov 11;24(5):589-602. (PMID: 24209604)
Prostate. 2014 Sep;74(13):1335-46. (PMID: 25053443)
J Immunol. 2012 Sep 15;189(6):3249-59. (PMID: 22875801)
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70. (PMID: 14967443)
Cancers (Basel). 2020 May 21;12(5):. (PMID: 32455621)
Oncotarget. 2017 May 9;8(19):31368-31385. (PMID: 28404896)
Front Immunol. 2020 Mar 04;11:364. (PMID: 32194568)
Exp Cell Res. 1989 Nov;185(1):73-85. (PMID: 2530103)
Oncotarget. 2015 Oct 27;6(33):34494-509. (PMID: 26460734)
Oncoimmunology. 2019 Sep 7;8(11):1659095. (PMID: 31646084)
Front Immunol. 2022 Apr 28;13:859785. (PMID: 35603186)
J Labelled Comp Radiopharm. 2019 Jun 30;62(8):533-540. (PMID: 30889625)
معلومات مُعتمدة: InterLabs-0031 Helmholtz International Lab
فهرسة مساهمة: Keywords: bispecific T cell engager; immunotherapy; prostate cancer; prostate stem cell antigen; radiation
المشرفين على المادة: 0 (Antibodies, Bispecific)
0 (Immunologic Factors)
تواريخ الأحداث: Date Created: 20220727 Date Completed: 20220728 Latest Revision: 20220731
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9324763
DOI: 10.3390/ijms23147922
PMID: 35887271
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms23147922